- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
Panelists discuss how the SUNLIGHT trial and real-world evidence support FTD/TPI with or without bevacizumab as an effective third-line option in metastatic colorectal cancer.
EP: 1.Overview of Available Third-Line Options in mCRC
EP: 2.Evidence Supporting FTD/TPI ± Bevacizumab in mCRC
EP: 3.Efficacy of Fruquintinib and Comparisons Across Agents in mCRC
EP: 4.Selecting Among Third-Line Therapies in Clinical Practice for mCRC
EP: 5.Leveraging Real-World Evidence in Sequencing Decisions for mCRC
EP: 6.Translating Real-World Outcomes in mCRC Into Patient Conversations
EP: 7.Incorporating Patient-Reported Outcomes in mCRC Into Shared Decision-Making
EP: 8.Real-World Evidence in mCRC: Special Populations and Safety Assessment
EP: 9.Defining Future Needs for Real-World Evidence in mCRC
EP: 10.Applying Third-Line Therapy in mCRC: Community vs Academic Settings
Panelists examine the SUNLIGHT trial, which evaluated trifluridine/tipiracil (FTD/TPI) alone vs in combination with bevacizumab. The addition of bevacizumab demonstrated enhanced outcomes, supporting its role in extending survival while maintaining tolerability.
The rationale for combining bevacizumab with FTD/TPI lies in its complementary mechanisms, offering potential synergy that translates to improved patient benefit.
They also note that real-world experiences largely align with trial data, reinforcing clinical confidence in the regimen’s effectiveness across diverse patient populations.
